Relapsing Neuromyelitis Optica Spectrum Disorder - An Insight

Introduction:

Neuromyelitis optica spectrum disorder (NMOSD) is a newer name given to a bunch of disorders. This includes neuromyelitis optica as well. This disorder is a demyelinating autoimmune (self-cells are destroyed) condition. The immune system attacks the protective sheath (myelin sheath), which surrounds the nerves.

What Is the Pathophysiology of Relapsing Neuromyelitis Optica Spectrum Disorder?

Antibodies against the water channel protein aquaporin 4 (AQP4) in the astrocytic foot process (helpful in the blood-brain barrier formation) cause neuromyelitis optica spectrum disorder and neuromyelitis optica. Optic neuritis (ON) or longitudinally extensive transverse myelitis (LETM) is the most commonly occurring in patients. Ninety percent of NMOSD patients will eventually experience clinical relapses and develop lifelong impairment, even though the majority of patients respond well to therapy with steroids and plasmapheresis (medical procedure in which blood plasma extracorporeal exchange, removal, and return happens) in the acute setting.

Clinical Presentation and Epidemiology:

• The third to fourth decade is when neuromyelitis optica usually manifests itself, and its incidence is estimated to be between 0.05 and 4.4 per one lakh people, with a 3:1 to 9:1 female predominance. NMO is a global condition. However, patients with Asian, African, and Hispanic ancestry are more likely to have it. The most prevalent clinical presentations are optic neuritis (ON)(optic nerve inflammation), area postrema syndrome (APS) - (nausea, vomiting, and hiccups for more than 2 days), and longitudinally extensive transverse myelitis- spinal cord inflammation (LETM) (more than three vertebral segments). Nevertheless, 60 percent of patients also have brain lesions, mostly in the periventricular regions in the third and fourth ventricles line, in the hypothalamus, thalamus, or corpus callosum.

• Clinically differentiating non-myelinating disorders (NMO) from more prevalent demyelinating disorders like multiple sclerosis (MS) is crucial because immunomodulatory therapies for multiple sclerosis (such as Natalizumab, Glatiramer acetate, and interferon-beta (IFN-β), have been demonstrated to be ineffective and sometimes harmful.

• NMOSD is not common.

• Although estimates vary, it is thought that approximately 15 thousand Americans suffer from it. The number is increasing as medical professionals improve in diagnosing NMOSD.

Gender: Four to ten times as many women as males are affected by the primary kind of NMOSD.

Age: Middle age is when NMOSD typically manifests.

Race: NMOSD is more common in white people than in persons of color. A greater percentage of people of color are also impacted, particularly those who are of Asian or African heritage.

Family History: Three percent of patients report having an NMOSD-affected family. However, about half have a history of another autoimmune disease, either personally or through family.

What Are the Causative Factors of Relapsing Neuromyelitis Optica Spectrum Disorder?

The root causative factor of relapsing neuromyelitis optica spectrum disorder is unknown. This condition usually appears following a severe infection or after an autoimmune disorder. The immune system releases antibodies which are proteins normally expelled into the bloodstream as a method to fight infection. But in the case of NMOSD, the body constructs an antibody called AQP4-IgG that destroys a protein that is useful for distribution of water across the cell membranes.

What Are the Usual Signs of Relapsing Neuromyelitis Optica Spectrum Disorder?

NMOSD patients can have severe adverse effects, like sudden blurred vision or partial or complete paralysis. Common signs and symptoms are as follows:

• Blurry vision or blindness that affects one or both eyes.

• Weakness or paralysis in the limbs region or arms.

• Painful spasms.

• Loss of sensation (numbness) throughout the body.

• Persistent nausea.

• Uncontrollable vomiting.

• Persistent (severe) hiccups.

• Bladder or bowel dysfunction.

• Sleeping problems.

What Are the Patterns of Neuromyelitis Optica Spectrum Disorder?

For approximately 90 percent of patients, it manifests as a relapsing-remitting condition, very similar to the most common forms of multiple sclerosis. This means patients experience relapses (episodes) that typically last for several days. These episodes are followed by recovery periods (remissions) that can last for weeks, months, or even years. Each relapse inflicts new damage, which can accumulate over time and result in significant disability.

What Is the Seasonality of Neuromyelitis Optica Spectrum Disorder?

For NMOSD and multiple sclerosis, the most prevalent types of relapse are optic neuritis and transverse myelitis. Before the age of thirty, optic neuritis appears to be more common in NMOSD, whereas transverse myelitis is more common after that age. In NMOSD, relapses were more severe. In NMOSD, there can be a spring-summer seasonal bias for relapses.

What Is the Relationship Between NMOSD and COVID 19?

• There have been reports of NMOSD clinical symptoms after coronavirus (COVID-19) vaccines and after severe-acute-respiratory-syndrome-related coronavirus (SARS-CoV-2) infections since the start of the COVID-19 pandemic. A complete temporal connection between SARS-CoV-2 infections, COVID-19 vaccines, and de novo and recurrent forms of NMOSD is demonstrated by this systematic review. However, association does not automatically imply causality.

• This study also stresses that any potential danger inferred from this study is greatly outweighed by the preventive advantages that the COVID-19 vaccination offers to both the individual and society at large. The study proposes a connection between vaccination exposure or COVID-19 infection and the pathogenic cascade that could result in the development of clinical NMOSD symptoms.

• Because of concerns that vaccines could cause clinical attacks in patients with neuromyelitis optica spectrum disorder (NMOSD), vaccination has long been controversial. The recent debate on the COVID-19 vaccine outcomes highlighted these worries. There have been reports of vaccination-induced NMOSD instances as well as relapses, although it is unclear if there is a direct or accidental connection.

Conclusion:

According to the available studies, transverse myelitis and optic neuritis are the most common recurrence types in NMOSD, and bouts of optic neuritis, especially initial attacks, are more common in NMOSD than MS. Only in NMOSD were area postrema presentations observed, which made for three percent of all relapses and nine percent of first relapses. In patients with NMOSD, optic neuritis attacks were observed more commonly at younger ages, but transverse myelitis episodes occurred more frequently at later ages. The incidence, severity, and length of relapses, as well as the need for acute immunotherapies. Similar to other research, a spinal cord lesion was the most common type of relapse in NMOSD, and the frequency seen in this study (48 percent ) is in the middle of earlier findings (36 to 63 percent).